Abstract
Being a woman and getting older are the main risk factors for breast cancer. While admitting the increasing prevalence of breast cancer among females globally, there is an increasing urge for widening the range of chemical compounds that can act as potential inhibitors for certain cancer target receptors. Current investigation involves virtually screening of 19 protein receptors having major role in signal transduction pathway of breast cancer development against 47 compounds present in Hemidesmus indicus. Virtual screening and supplementary analysis were performed using freely available softwares, tools and online servers. To obtain meaningful results, a comparative scenario was created by screening FDA-approved drugs/drug analogues against the same 19 receptors by keeping all the parameters same as to that of ligands. Two ligands namely Taraxasteryl acetate and Rutin were found to be the best ligands with high binding affinity towards six protein receptors establishing strong receptor ligand interactions. Furthermore, the major volatile compound, a high demand flavouring agent and an isomer of vanillin, namely 2-hydroxy-4-methoxy benzaldehyde (MBALD) specifically found in the roots of Hemidesmus, was quantified by RP-HPLC using a reverse phase C-18 column. The methanolic extract of fresh roots was found to contain 0.221 mg of MBALD/gram of tissue. From the current investigation, it could be surmised that Hemidesmus indicus had demonstrated its potential in both pharmaceuticals and the food industry.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Addie M, Ballard P, Buttar D et al (2013) Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem 56:2059–2073. https://doi.org/10.1021/jm301762v
Akhtar S, Benter IF (2013) The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. BioImpacts 3:5–9. https://doi.org/10.5681/bi.2013.008
Anantharaju P, Reddy B, Padukudru M et al (2017) Naturally occurring benzoic acid derivatives retard cancer cell growth by inhibiting histone deacetylases (HDAC). Cancer Biol Ther 18:492–504. https://doi.org/10.1080/15384047.2017.1324374
Ananthi R, Chandra N, Santhiya ST (2010) Protective effect of Hemidesmus indicus R.Br. root extract against cisplatin-induced cytogenetic damage in mouse bone marrow cells. Genet Mol Biol 33:182–185. https://doi.org/10.1590/S1415-47572010005000011
Banerji A, Banerji J, Das M, et al (2017) Some aspects of investigation of the indian medicinal plant Hemidesmus indicus R. Br.: chemical constituents and anti-diabetic activity. Available online www.jocpr.com. J Chem Pharm Res 2017:50–64
Baselga J, Albanell J, Ruiz A et al (2005) Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23:5323–5333. https://doi.org/10.1200/JCO.2005.08.326
Baskar R, Lee KA, Yeo R, Yeoh K-W (2012) Cancer and radiation therapy: current advances and future directions. Int J Med Sci 9:193–199. https://doi.org/10.7150/ijms.3635
Boyle N, Banck M, James C, et al (2011) Open Babel: an open chemical toolbox - 1758–2946–3–33.pdf. 1–14
Chen P, Lee N, Hu W et al (2016) Spectrum and Degree of CDK Drug interactions predicts clinical performance. Mol Cancer Ther 15:2273–2281. https://doi.org/10.1158/1535-7163.MCT-16-0300
Chidambara Murthy KN, Rajasekaran T, Giridhar P, Ravishankar GA (2006) Antioxidant property of Decalepis hamiltonii wight and arn. Indian J Exp Biol 44:832–837
Chohan T, Qayyum A, Rehman K et al (2018) An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers. Biomed Pharmacother 107:1326–1341. https://doi.org/10.1016/j.biopha.2018.08.116
Cragg G, Newman D (2013) Natural products: a continuing source of novel drug leads. Biochim Biophys Acta Gen Subj 1830:3670–3695. https://doi.org/10.1016/j.bbagen.2013.02.008
Dallakyan S, Olson A (2015) Small-molecule library screening by docking with PyRx. Methods Mol Biol:243–250
Darekar R, Khetre A, Singh S, Damle M (2009) HPTLC quantitation of 2-hydroxy-4-methoxybenzaldehyde in Hemidesmus indicus R.Br. root powder and extract. J Planar Chromatogr Mod TLC 22:453–456. https://doi.org/10.1556/JPC.22.2009.6.13
De S, Dermawan T, Stark R (2014) EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells. Proc Natl Acad Sci USA 111:11721–11726. https://doi.org/10.1073/pnas.1412390111
Ding L, Cao J, Lin W et al (2020) The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci 21:1–28. https://doi.org/10.3390/ijms21061960
Dulaney C, Marcrom S, Stanley J, Yang S (2017) Poly(ADP-ribose) polymerase activity and inhibition in cancer. Semin Cell Dev Biol 63:144–153. https://doi.org/10.1016/j.semcdb.2017.01.007
Dziadkowiec K, Gasiorowska E, Nowak-Markwitz E, Jankowska A (2016) PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny 15:215–219. https://doi.org/10.5114/pm.2016.65667
Elsayed H, Ebrahim H, Mohyeldin M et al (2017) Rutin as a novel c-Met Inhibitory Lead For The Control Of Triple Negative Breast Malignancies. Nutr Cancer 69:1256–1271. https://doi.org/10.1080/01635581.2017.1367936
Eroles P, Bosch A, Alejandro Pérez-Fidalgo J, Lluch A (2012) Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev 38:698–707. https://doi.org/10.1016/j.ctrv.2011.11.005
FDA.gov (2020) FDA grants accelerated approval to pembrolizumab forlocally recurrent unresectable or metastatic triple negativebreast cancer. https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-triple-negative-breast-cancer-has-spread-not-responded-other-treatments. Accessed 27 Mar 2021
Ferruzzi L, Turrini E, Burattini S et al (2013) Hemidesmus indicus induces apoptosis as well as differentiation in a human promyelocytic leukemic cell line. J Ethnopharmacol 147:84–91. https://doi.org/10.1016/j.jep.2013.02.009
Gam L-H (2012) Breast cancer and protein biomarkers. World J Exp Med. https://doi.org/10.5493/wjem.v2.i5.86
Gao X, Liu X, Lu Y et al (2019) PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation. Breast Cancer 26:663–671. https://doi.org/10.1007/s12282-019-00966-3
Hamdouchi C, Keyser H, Collins E et al (2004) The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines. Mol Cancer Ther 3:1–9
Hillig RC, Sautier B, Schroeder J et al (2019) Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Proc Natl Acad Sci USA 116:2551–2560. https://doi.org/10.1073/pnas.1812963116
Holder S, Zemskova M, Zhang C et al (2007) Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 6:163–172. https://doi.org/10.1158/1535-7163.MCT-06-0397
Hwang SY, Park S, Kwon Y (2019) Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther 199:30–57. https://doi.org/10.1016/j.pharmthera.2019.02.006
Ijaz M, Wang F, Shahbaz M et al (2017) The Role of Grb2 in cancer and peptides as Grb2 antagonists. Protein Pept Lett. https://doi.org/10.2174/0929866525666171123213148
Iqbal N, Iqbal N (2014) Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014:1–9. https://doi.org/10.1155/2014/852748
Ishikawa T, Seto M, Banno H et al (2011) Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem 54:8030–8050. https://doi.org/10.1021/jm2008634
Isshiki Y, Kohchi Y, Iikura H et al (2011) Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. Bioorg Med Chem Lett 21:1795–1801. https://doi.org/10.1016/j.bmcl.2011.01.062
Jackson G, Lee V (1997) Insulin-like parameters growth in breast and factor cancer : binding with and insulin receptor correlation clinical. Clin Cancer Res 3:103–109
Kawlni L, Bora M, Upadhyay SN et al (2017) Pharmacological and therapeutic profile of anantamula (hemidesmus indicus (l.) R. Br.): a comprehensive review. Int J Ayurveda Pharma Res 5:49–57
Knight S, Adams N, Burgess J et al (2010) Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett 1:39–43. https://doi.org/10.1021/ml900028r
Manjulatha K, Saritha K, Setty H (2014) Phytochemistry, pharmacology and therapeutics of Hemidesmus indicus (L.) R. Br. Med Plants Phytochem Pharmacol Ther. https://doi.org/10.1017/CBO9781107415324.004
More D, Mali P (2018) A review article on species used as sarivain different regions of India: hemidesmus indicus, Ichnocrpus frutescens, Decalepis hamiltoni and Cryptolepis buchanani. Ayurlog Natl J Res Ayurved Sci 6:1–13
Murugan N, Mishra B, Paul B (2018) Antioxidant, antibacterial and GC-MS analysis of methanol root extract of Hemidesmus indicus (L.) R. Br J Pharmacogn Phytochem 7:1669–1674
Nagarajan S, Jagan Mohan Rao L, Gurudutt N (2001) Chemical composition of the volatiles of Hemidesmus indicus R. Br Flavour Fragr J 16:212–214. https://doi.org/10.1002/ffj.985
Ogura K, Shiga T, Yokochi M et al (2008) Solution structure of the Grb2 SH2 domain complexed with a high-affinity inhibitor. J Biomol NMR 42:197–207. https://doi.org/10.1007/s10858-008-9272-0
Okamoto K, Ikemori-Kawada M, Jestel A et al (2015) Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett 6:89–94. https://doi.org/10.1021/ml500394m
Pal S, Moulik S, Dutta A, Chatterjee A (2014) Extracellular matrix protein laminin induces matrix metalloproteinase-9 in human breast cancer cell line MCF-7. Cancer Microenviron 7:71–78. https://doi.org/10.1007/s12307-014-0146-6
Papadimitriou M, Mountzios G, Papadimitriou CA (2018) The role of PARP inhibition in triple-negative breast cancer: unraveling the wide spectrum of synthetic lethality. Cancer Treat Rev 67:34–44. https://doi.org/10.1016/j.ctrv.2018.04.010
Park H, Ito K, Olcott W et al (2015) PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2+ breast cancer cells by inducing Bim. Breast Cancer Res 17:1–13. https://doi.org/10.1186/s13058-015-0594-z
Prathibha Devi P, Devi Cherku P, Rama Devi B et al (2016) Estimation of 2-hydroxy-4-methoxybenzaldehyde, lupeol and other unreported compounds in an elite ecotype of Hemidesmus indicus (L.) R. BR An Int J Ann Phytomed 5:51–58
Ramos PAB, Guerra ÂR, Guerreiro O, et al (2017) Antiproliferative effects of Cynara cardunculus L. Var. altilis (DC) lipophilic extracts. Int J Mol Sci. https://doi.org/10.3390/ijms18010063
Rathi N, Harwalkar K, Jayashree V, et al (2017) 2-hydroxy-4-methoxybenzaldehyde, an astounding food flavoring metabolite: a review. Asian J Pharm Clin Res 10:105–110. https://doi.org/10.22159/ajpcr.2017.v10i10.19729
Russo J, Russo H (2006) The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 102:89–96. https://doi.org/10.1016/j.jsbmb.2006.09.004
Savage P, Blanchet-Cohen A, Revil T et al (2017) A targetable EGFR-dependent tumor-initiating program in breast cancer. Cell Rep 21:1140–1149. https://doi.org/10.1016/j.celrep.2017.10.015
Sharma HP, Plants M, Analysis G (2017) GC-MS analysis of a medicinal plant: Hemidesmus indicus. Bot Reena Keywords : 53–55
Song M, Bode AM, Dong Z, Lee MH (2019) AKt as a therapeutic target for cancer. Cancer Res 79:1019–1031. https://doi.org/10.1158/0008-5472.CAN-18-2738
Srabovic N, Mujagic Z, Mujanovic-Mustedanagic J et al (2013) Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor A. Int J Breast Cancer 2013:1–6. https://doi.org/10.1155/2013/746749
Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277:46265–46272. https://doi.org/10.1074/jbc.M207135200
Swathi S, Rani R, Amareshwari P, Venkatesh K (2019) Phytochemical and pharmacological benefits of Hemidesmus indicus: an updated review. J Pharmacogn Phytochem 8:256–262
Thabrew M, Mitry R, Morsy A, Hughes D (2005) Cytotoxic effects of a decoction of Nigella sativa, Hemidesmus indicus and Smilax glabra on human hepatoma HepG2 cells. Life Sci 77:1319–1330. https://doi.org/10.1016/j.lfs.2005.01.022
Thakur M, Birudukota S, Swaminathan S et al (2017) Co-crystal structures of PTK6: With Dasatinib at 2.24 Å, with novel imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 Å resolution. Biochem Biophys Res Commun 482:1289–1295. https://doi.org/10.1016/j.bbrc.2016.12.030
Thorsell A-G, Ekblad T, Karlberg T et al (2017) Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors. J Med Chem 60:1262–1271. https://doi.org/10.1021/acs.jmedchem.6b00990
Tresaugues L, Roos A, Arrowsmith C, et al (2013) Crystal structure of VEGFR1 in complex with N-(4-Chlorophenyl)-2-((pyridin-4-ylmethyl) amino) benzamide. RCSB PDB
Tsui T, Miller W (2015) Cancer-associated mutations in breast tumor kinase/PTK6 differentially affect enzyme activity and substrate recognition. Biochemistry 54:3173–3182. https://doi.org/10.1021/acs.biochem.5b00303
Tucker J, Klein T, Breed J et al (2014) Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4. Structure 22:1764–1774. https://doi.org/10.1016/j.str.2014.09.019
Vajdos F, Hoth L, Geoghegan K et al (2007) The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene. Protein Sci 16:897–905. https://doi.org/10.1110/ps.062729207
Version A, Morris GM, Goodsell DS, et al (2014) AutoDock Version 4.2. 1–69
Wang J, Liu H, Zhao J et al (2010) Antimicrobial and antioxidant activities of the root bark essential oil of Periploca sepium and its main component 2-hydroxy-4-methoxybenzaldehyde. Molecules 15:5807–5817. https://doi.org/10.3390/molecules15085807
Ward R, Colclough N, Challinor M et al (2015) Structure-guided design of highly selective and potent covalent inhibitors of ERK1/2. J Med Chem 58:4790–4801. https://doi.org/10.1021/acs.jmedchem.5b00466
Weiss MC (2020) Molecular subtypes of breast cancer. https://www.breastcancer.org/. Accessed 10 Jul 2019
Wu J, Li W, Craddock B et al (2008) Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor. EMBO J 27:1985–1994. https://doi.org/10.1038/emboj.2008.116
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bansod, A.A., Ramasamy, G., Nathan, B. et al. Exploring the endogenous potential of Hemidesmus indicus against breast cancer using in silico studies and quantification of 2-hydroxy-4-methoxy benzaldehyde through RP-HPLC. 3 Biotech 11, 235 (2021). https://doi.org/10.1007/s13205-021-02768-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13205-021-02768-x